Company Profile

Genzyme Corporation (AKA: Biomatrix Inc~genzyme Biosurgery Corporation)
Profile last edited on: 10/21/22      CAGE: 1HBD8      UEI: X2XMAQLR9DA8

Business Identifier: Rare Genetic Diseases, Multiple Sclerosis, Cardiovascular Disease, Endocrinology
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

500 Kendall Square
Cambridge, MA 02142
   (617) 252-7500
Location: Multiple
Congr. District: 07
County: Middlesex

Public Profile

In February 2011, Genzyme Corporation was acquired by French drug maker Sanofi-Aventis. Genzyme Corporation was founded as a biotechnology and health care products company focused on developing innovative products and services for major unmet medical needs. Genzyme Corp. has three divisions. Each division has its own common stock intended to reflect its value and track its performance. Genzyme General develops and markets therapeutic and surgical products and diagnostic products and services. Genzyme Tissue Repair is a leading developer of biological products for the treatment of cartilage damage, severe burns, chronic skin ulcers, and neurological disorders. Genzyme Molecular Oncology develops molecular approaches to cancer diagnosis and therapy through genomics, gene therapy, genetic diagnostics, and a small-molecule combinatorial chemistry drug discovery program. Genzyme Molecular Oncology's common stock is now publicly traded under the NASDAQ symbol GZMO. Genzyme Corporation is a diversified human healthcare company with product development, manufacturing and market capabilities in biotherapeutics, diagnostic products and services, and pharmaceuticals. The company's product portfolio focuses on rare genetic disorders as well as organ transplant, osteoarthritis, and renal disease. One of its main products, Cerezyme, is a leading treatment for Gaucher's disease, a rare enzyme-deficiency condition. Genzyme also is involved in drug development and genetic testing and other services. Genzyme Molecular Oncology develops gene-based cancer diagnosis and treatment products, and Genzyme Biosurgery primarily makes orthopedic medical and surgical products. In September 2010, Genzyme Corporation had sold its Genetics unit to Laboratory Corporation of America

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1997 1 NIH $100,000
Project Title: Embryonic Stem Cells In Pharmaceutical Production
1997 1 NIH $100,000
Project Title: Aerosol Alpha 1 Proteinase Inhibitor for Cystic Fibrosis
1990 2 NIH $550,000
Project Title: Purification of high mannose oliogosaccharides
1986 1 NIH $50,000
Project Title: Large Scale Purification of Acidic-D-Mannosidase
1985 1 NIH $50,000
Project Title: Monoclonal antibodies directed against cytokines

Key People / Management

  Endre Balazs -- former CEO

  David Meeker -- President and Chief Executive Officer

  Shan Chung

  Yann Echelard

  Shirish Hirani

  Donald S Masters

  Thomas P (Tom) Mathers -- Former President

  James R Rasmussen

  Henri Termeer -- Founder abd Past President

  Carol A Ziomek